Author: admin

The Herpes Zoster Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Herpes Zoster Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Herpes Zoster Market.

Some of the key takeaways from the Herpes Zoster Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Herpes Zoster treatment therapies with a considerable amount of success over the years. 
• Herpes Zoster companies working in the treatment market are CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax Technologies Corporation, EyeGene, Curevo Inc, Changchun BCHT Biotechnology, and others, are developing therapies for the Herpes Zoster treatment 

• Emerging Herpes Zoster therapies in the different phases of clinical trials are- VZV Vaccine, Herpes Zoster vaccine, mRNA-1468, GLS5100, Z-1018, EG-HZ, CRV101, Varicella zoster virus vaccine, and others are expected to have a significant impact on the Herpes Zoster market in the coming years.
• In January 2024, Jiangsu Recbio Technology, headquartered in China, has reported encouraging findings from its initial human trial of a shingles vaccine. This trial assessed REC610, an innovative adjuvanted recombinant shingles vaccine, in comparison to GSK’s Shingrix. REC610 aims to stimulate the generation of significant quantities of VZV glycoprotein E (gE)-specific CD4+ T cells and antibodies, with the goal of preventing shingles among individuals aged 40 and older.   
• In December 2022, Jiangsu Recbio Technology Co., Ltd. disclosed that they have secured clinical trial authorization for their innovative adjuvanted recombinant shingles vaccine, REC610, from the Philippines’ Food and Drug Administration.

Herpes Zoster Overview

Herpes zoster (HZ), also called as Shingles, is a neurocutaneous disease that is generally caused by the reactivation ofvaricella-zoster virus (VZV) from a latent infection of dorsal sensory or cranial nerve ganglia following primary infection withVZV before in life. VZV is explicitly a human virus that belongs to the α-herpes virus family

Get a Free Sample PDF Report to know more about Herpes Zoster Pipeline Therapeutic Assessment-

delveinsight.com/report-store/herpes-zoster-pipeline-insight

Emerging Herpes Zoster Drugs Under Different Phases of Clinical Development Include:

• VZV Vaccine: CPL Biologics
• Herpes Zoster vaccine: EuBiologics
• mRNA-1468: Moderna
• GLS5100: Gene One Life Science
• Z-1018: Dynavax Technologies Corporation
• EG-HZ: EyeGene
• CRV101: Curevo Inc
• Varicella zoster virus vaccine: Changchun BCHT Biotechnology

Herpes Zoster Route of Administration

Herpes Zoster pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Herpes Zoster Molecule Type

Herpes Zoster Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Herpes Zoster Pipeline Therapeutics Assessment

• Herpes Zoster Assessment by Product Type
• Herpes Zoster By Stage and Product Type
• Herpes Zoster Assessment by Route of Administration
• Herpes Zoster By Stage and Route of Administration
• Herpes Zoster Assessment by Molecule Type
• Herpes Zoster by Stage and Molecule Type

DelveInsight’s Herpes Zoster Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Herpes Zoster product details are provided in the report. Download the Herpes Zoster pipeline report to learn more about the emerging Herpes Zoster therapies

Some of the key companies in the Herpes Zoster Therapeutics Market include:

Key companies developing therapies for Herpes Zoster are – Viatris Inc., Takeda Pharmaceutical Company Limited, Novartis AG, GlaxoSmithKline PLC, Merck & Co. Inc., Apotex Inc., Pfizer Inc., Hetero Drug (Camber Pharmaceuticals, Inc.), Cipla Inc., and others.

Herpes Zoster Pipeline Analysis:

The Herpes Zoster pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Herpes Zoster with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Herpes Zoster Treatment.
• Herpes Zoster key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Herpes Zoster Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Herpes Zoster market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Herpes Zoster drugs and therapies

Herpes Zoster Pipeline Market Drivers

• Increasing awareness and high demand for shingles prevention, rising incidence of herpes zoster, increasing awareness and high demand for shingles prevention, favorable reimbursement and funding policies are some of the important factors that are fueling the Herpes Zoster Market.

Herpes Zoster Pipeline Market Barriers

• However, high cost of vaccines, lack of vaccine compliance and knowledge about Shingles prevention, logistical and storage barriers, side effects associated with the current treatment options and other factors are creating obstacles in the Herpes Zoster Market growth.

Scope of Herpes Zoster Pipeline Drug Insight    

• Coverage: Global
• Key Herpes Zoster Companies: CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax Technologies Corporation, EyeGene, Curevo Inc, Changchun BCHT Biotechnology, and others
• Key Herpes Zoster Therapies: VZV Vaccine, Herpes Zoster vaccine, mRNA-1468, GLS5100, Z-1018, EG-HZ, CRV101, Varicella zoster virus vaccine, and others
• Herpes Zoster Therapeutic Assessment: Herpes Zoster current marketed and Herpes Zoster emerging therapies
• Herpes Zoster Market Dynamics: Herpes Zoster market drivers and Herpes Zoster market barriers 

Request for Sample PDF Report for Herpes Zoster Pipeline Assessment and clinical trials

Table of Contents

1. Herpes Zoster Report Introduction

2. Herpes Zoster Executive Summary

3. Herpes Zoster Overview

4. Herpes Zoster- Analytical Perspective In-depth Commercial Assessment

5. Herpes Zoster Pipeline Therapeutics

6. Herpes Zoster Late Stage Products (Phase II/III)

7. Herpes Zoster Mid Stage Products (Phase II)

8. Herpes Zoster Early Stage Products (Phase I)

9. Herpes Zoster Preclinical Stage Products

10. Herpes Zoster Therapeutics Assessment

11. Herpes Zoster Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Herpes Zoster Key Companies

14. Herpes Zoster Key Products

15. Herpes Zoster Unmet Needs

16 . Herpes Zoster Market Drivers and Barriers

17. Herpes Zoster Future Perspectives and Conclusion

18. Herpes Zoster Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Herpes Zoster Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax

DelveInsight’s “Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hereditary Angioedema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Angioedema Market Forecast

Some of the key facts of the Hereditary Angioedema Market Report: 

• The Hereditary Angioedema market size was valued approximately USD 2,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Throughout all the Seven Major Markets (7MM), the United States consistently maintained the largest market size, estimated to be nearly USD 2,000 million in 2023. This figure is projected to increase during the forecast period from 2024 to 2034.
• In Feb 2024, BioCryst introduced ORLADEYO (berotralstat) in Italy.
• In Jan 2024, Ionis disclosed favorable topline findings from the Phase III OASIS-HAE study evaluating the investigational drug donidalorsen in individuals with hereditary angioedema. Based on these results, Ionis is in the process of preparing a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). 
• In Dec 2023, CSL Behring has declared that the FDA has acknowledged a Biologics License Application (BLA) for garadacimab (CSL312) as a monthly prophylactic treatment for hereditary angioedema (HAE).
• In 2023, the total number of diagnosed prevalent cases of hereditary angioedema (HAE) across the Seven Major Markets (7MM) was 13,900. It is anticipated that this figure will experience a significant compound annual growth rate (CAGR) by the year 2034.
• Within the EU4 and the UK region, the United Kingdom exhibited the largest diagnosed prevalent population of hereditary angioedema (HAE), with almost 1,400 cases, followed closely by Germany, which reported 1,300 diagnosed prevalent cases in 2023. Conversely, Spain and Italy had the lowest diagnosed prevalent populations, each with fewer than 1,000 cases in 2023.
• The evolving array of drugs in development for Hereditary Angioedema (HAE) encompasses numerous options for both preventive measures and treatment. These include garadacimab, donidalorsen, KVD900, NTLA2002, and others, which target a broad spectrum of mechanisms. Ongoing research and clinical trials hold the promise of potentially reshaping the market landscape for HAE.
• Potential therapeutic targets include blocking the bradykinin-B2-receptor, plasma kallikrein inhibitor, inhibiting factor XII (for example, by using a blocking antibody), and preventing the cleavage of prekallikrein. In addition, a small number of gene treatments are being developed to treat Hereditary Angioedema; they will aid in the treatment of recently discovered mutations such FXII and PLG HAE.
• Key Hereditary Angioedema Companies: KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, KalVista Pharmaceuticals, CSL Behring, Shire, and others
• Key Hereditary Angioedema Therapies: KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
• The Hereditary Angioedema epidemiology based on gender analyzed that the diagnosed prevalent cases of Hereditary Angioedema in the 7MM varied according to gender, with prevalent cases higher in females than males
• The Hereditary Angioedema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Angioedema pipeline products will significantly revolutionize the Hereditary Angioedema market dynamics.

Hereditary Angioedema Overview

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body, including the skin, mucous membranes, and internal organs. This swelling, known as angioedema, typically affects areas such as the face, hands, feet, gastrointestinal tract, and airway. HAE attacks can occur suddenly and without warning, and they may last for several days.

Get a Free sample for the Hereditary Angioedema Market Report:

https://www.delveinsight.com/report-store/hereditary-angioedema-market

Hereditary Angioedema Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hereditary Angioedema Epidemiology Segmentation:

The Hereditary Angioedema market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Hereditary Angioedema
• Prevalent Cases of Hereditary Angioedema by severity
• Gender-specific Prevalence of Hereditary Angioedema
• Diagnosed Cases of Episodic and Chronic Hereditary Angioedema

Download the report to understand which factors are driving Hereditary Angioedema epidemiology trends @ Hereditary Angioedema Epidemiology Forecast

Hereditary Angioedema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched during the study period. The analysis covers Hereditary Angioedema market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hereditary Angioedema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hereditary Angioedema Therapies and Key Companies

• KVD900: KalVista Pharmaceuticals
• NTLA-2002: Intellia Therapeutics
• BMN 331: BioMarin Pharmaceutical
• Garadacimab: CSL Behring
• Donidalorse: Ionis Pharmaceuticals
• STAR-0215: Astria Therapeutics
• PHA121: Pharvaris Netherlands B.V
• NTLA-2002: Intellia Therapeutics
• TAK-743: Takeda
• KVD900: KalVista Pharmaceuticals
• CSL312: CSL Behring
• Lanadelumab: Shire

Discover more about therapies set to grab major Hereditary Angioedema market share @ Hereditary Angioedema Treatment Market

Hereditary Angioedema Market Strengths

• Increasing identification of a novel genetic mutation in various regions warranting further focus on the types and associated pathophysiology, including recognition of hormonal changes

Hereditary Angioedema Market Opportunities

• Proliferating demand for therapies with improved patient compliance, fewer side effects, improved resistance profile, and long-acting therapies

Scope of the Hereditary Angioedema Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hereditary Angioedema Companies: KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, KalVista Pharmaceuticals, CSL Behring, Shire, and others
• Key Hereditary Angioedema Therapies: KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorse, STAR-0215, PHA121, NTLA-2002, TAK-743, KVD900, CSL312, Lanadelumab, and others
• Hereditary Angioedema Therapeutic Assessment: Hereditary Angioedema current marketed and Hereditary Angioedema emerging therapies
• Hereditary Angioedema Market Dynamics: Hereditary Angioedema market drivers and Hereditary Angioedema market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Hereditary Angioedema Unmet Needs, KOL’s views, Analyst’s views, Hereditary Angioedema Market Access and Reimbursement 

To know more about Hereditary Angioedema companies working in the treatment market, visit @ Hereditary Angioedema Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Hereditary Angioedema Market Report Introduction

2. Executive Summary for Hereditary Angioedema

3. SWOT analysis of Hereditary Angioedema

4. Hereditary Angioedema Patient Share (%) Overview at a Glance

5. Hereditary Angioedema Market Overview at a Glance

6. Hereditary Angioedema Disease Background and Overview

7. Hereditary Angioedema Epidemiology and Patient Population

8. Country-Specific Patient Population of Hereditary Angioedema 

9. Hereditary Angioedema Current Treatment and Medical Practices

10. Hereditary Angioedema Unmet Needs

11. Hereditary Angioedema Emerging Therapies

12. Hereditary Angioedema Market Outlook

13. Country-Wise Hereditary Angioedema Market Analysis (2019–2032)

14. Hereditary Angioedema Market Access and Reimbursement of Therapies

15. Hereditary Angioedema Market Drivers

16. Hereditary Angioedema Market Barriers

17.  Hereditary Angioedema Appendix

18. Hereditary Angioedema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hereditary Angioedema Market Size was ~USD 2,400 Million in 2023 to Witness Growth by 2032, Estimates DelveInsight | KalVista Pharma, Intellia Therapeutics, BioMarin Phama, CSL Behring, Ionis Pharma

DelveInsight’s “Huntington’s Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Huntington’s Disease, historical and forecasted epidemiology as well as the Huntington’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Huntington’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Huntington’s Disease Market Forecast

Some of the key facts of the Huntington’s Disease Market Report: 

• The Huntington’s Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In April 2023, Prilenia Therapeutics disclosed the key findings from the Phase III PROOF-HD clinical trial in Huntington’s Disease.
• In August 2023, The US FDA sanctioned the use of INGREZZA (valbenazine) capsules, a VMAT2 inhibitor, for managing chorea in adults with Huntington’s disease.
• In February 2023, The US FDA authorized AUSTEDO XR, a novel once-daily tablet designed to address tardive dyskinesia and chorea associated with Huntington’s disease in adults. AUSTEDO XR represents an extended-release formulation of the previously available AUSTEDO taken twice daily.
• In the 7MM population, there will be 81,000 cases of Huntington’s disease overall in 2022. In the 7MM, the US had the highest number of frequently occurring cases of Huntington’s disease, followed by Germany
• In Germany, there were correspondingly 300, 700, 1,200, and 2,000 cases of Huntington’s disease among people aged 20 to 39, 40 to 49, 50 to 59, and 60 or older in 2022.
• In the 7MM, there were 39,000 treated instances of Huntington’s disease overall in 2022; however, this number could rise during the projection period (2023–2022)
• Key Huntington’s Disease Companies: Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Roche, Ionis Pharmaceuticals, Neurocrine Biosciences, Vaccinex, Azevan Pharmaceuticals, WaVe life Sciences, Luye Pharma Group, SOLA Biosciences, and others
• Key Huntington’s Disease Therapies: Pridopidine(ACR-16; Huntexil), Ingrezza (valbenazine), SOM3355(bevantolol), ANX005, VX15/2503 (pepinemab), SAGE-718, AMT-130/ intrastriatal rAAV5-miHTT, RO7234292, Tominersen, Valbenazine, Pepinemab, SRX246, WVE-003, LPM3770164, SOL-175, and others
• The Huntington’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Huntington’s Disease pipeline products will significantly revolutionize the Huntington’s Disease market dynamics.

Huntington’s Disease Overview

Huntington’s disease (HD) is a progressive and inherited neurological disorder that affects the brain’s nerve cells, leading to gradual deterioration of cognitive, motor, and psychiatric functions. HD is caused by a mutation in the HTT gene, which produces a protein called huntingtin. The mutation leads to the production of an abnormal form of the huntingtin protein, which accumulates in neurons and disrupts their function.

Get a Free sample for the Huntington’s Disease Market Report:

https://www.delveinsight.com/report-store/huntingtons-disease-market

Huntington’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Huntington’s Disease Epidemiology Segmentation:

The Huntington’s Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Huntington’s Disease
• Prevalent Cases of Huntington’s Disease by severity
• Gender-specific Prevalence of Huntington’s Disease
• Diagnosed Cases of Episodic and Chronic Huntington’s Disease

Download the report to understand which factors are driving Huntington’s Disease epidemiology trends @ Huntington’s Disease Epidemiology Forecast

Huntington’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Huntington’s Disease market or expected to get launched during the study period. The analysis covers Huntington’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Huntington’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Huntington’s Disease Therapies and Key Companies

• Pridopidine(ACR-16; Huntexil): Prilenia Therapeutics
• Ingrezza (valbenazine): Neurocrine Biosciences
• SOM3355(bevantolol): Som Biotech
• ANX005: Annexon Biosciences
• VX15/2503 (pepinemab): Vaccinex
• SAGE-718: Sage Therapeutics
• AMT-130/ intrastriatal rAAV5-miHTT: UniQure Biopharma
• RO7234292: Roche
• Tominersen: Ionis Pharmaceuticals
• Valbenazine: Neurocrine Biosciences
• Pepinemab: Vaccinex
• SRX246: Azevan Pharmaceuticals
• WVE-003: WaVe life Sciences
• LPM3770164: Luye Pharma Group
• SOL-175: SOLA Biosciences

Discover more about therapies set to grab major Huntington’s Disease market share @ Huntington’s Disease Treatment Market

Huntington’s Disease Market Strengths

• As adult-onset Huntington’s disease is more common than juvenile Huntington’s disease, so with growing geriatricpopulation more elderly patients will be diagnosed with HD knowledge

Huntington’s Disease Market Opportunities

• Huntington’s disease is a rare condition thus, companies developing treatment options for the same can possess several advantages like premium pricing, an Orphan Designation, which comes along with 7 years of market exclusivity in the US, clinical trial subsidies, reduced regulatory fees, and several other benefits.

Scope of the Huntington’s Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Huntington’s Disease Companies: Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Roche, Ionis Pharmaceuticals, Neurocrine Biosciences, Vaccinex, Azevan Pharmaceuticals, WaVe life Sciences, Luye Pharma Group, SOLA Biosciences, and others
• Key Huntington’s Disease Therapies: Pridopidine(ACR-16; Huntexil), Ingrezza (valbenazine), SOM3355(bevantolol), ANX005, VX15/2503 (pepinemab), SAGE-718, AMT-130/ intrastriatal rAAV5-miHTT, RO7234292, Tominersen, Valbenazine, Pepinemab, SRX246, WVE-003, LPM3770164, SOL-175, and others
• Huntington’s Disease Therapeutic Assessment: Huntington’s Disease current marketed and Huntington’s Disease emerging therapies
• Huntington’s Disease Market Dynamics: Huntington’s Disease market drivers and Huntington’s Disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Huntington’s Disease Unmet Needs, KOL’s views, Analyst’s views, Huntington’s Disease Market Access and Reimbursement 

To know more about Huntington’s Disease companies working in the treatment market, visit @ Huntington’s Disease Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Huntington’s Disease Market Report Introduction

2. Executive Summary for Huntington’s Disease

3. SWOT analysis of Huntington’s Disease

4. Huntington’s Disease Patient Share (%) Overview at a Glance

5. Huntington’s Disease Market Overview at a Glance

6. Huntington’s Disease Disease Background and Overview

7. Huntington’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Huntington’s Disease 

9. Huntington’s Disease Current Treatment and Medical Practices

10. Huntington’s Disease Unmet Needs

11. Huntington’s Disease Emerging Therapies

12. Huntington’s Disease Market Outlook

13. Country-Wise Huntington’s Disease Market Analysis (2019–2032)

14. Huntington’s Disease Market Access and Reimbursement of Therapies

15. Huntington’s Disease Market Drivers

16. Huntington’s Disease Market Barriers

17.  Huntington’s Disease Appendix

18. Huntington’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Huntington’s Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech

DelveInsight’s “Hypoxia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypoxia, historical and forecasted epidemiology as well as the Hypoxia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hypoxia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypoxia Market Forecast

Some of the key facts of the Hypoxia Market Report: 

• The Hypoxia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to Biogen’s 2022 data, approximately two million individuals are projected to experience a stroke annually in both the United States and the European Union.
• According to a study led by Myriam Lacerte et al. (2020), the incidence rates of Hypoxic Brain Injury are estimated to be around 50 per 100,000 population, with survival-to-discharge rates at approximately 8%. This translates to over 10,000 patients per year in the United States alone.
• Key Hypoxia Companies: Keros Therapeutics, Inc., Diffusion Pharmaceuticals, Reven Pharmaceuticals, ReAlta Life Sciences, Inc, Partner Therapeutics, Inc, Teclison Ltd., Merck Sharp & Dohme, Eli Lilly and Company, Biogen, AesRx, LLC, Threshold Pharmaceuticals, GlaxoSmithKline, Roche, Global Blood Therapeutics, Akebia Therapeutics, and others
• Key Hypoxia Therapies: RKER-012, Trans Sodium Crocetinate, Rejuveinix, RLS-0071, Sargramostim, Tirapazamine, Belzutifan, Tirzepatide, TMS-007, Aes-103, TH-302, GSK2256294, RO7070179, GBT440, AKB-6548, and others
• The Hypoxia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypoxia pipeline products will significantly revolutionize the Hypoxia market dynamics.

Hypoxia Overview

Hypoxia refers to a condition where there is a deficiency in the amount of oxygen reaching the body’s tissues. This can occur when the oxygen supply to tissues is insufficient, leading to inadequate oxygenation of cells. Hypoxia can be caused by various factors, including low oxygen levels in the environment (such as at high altitudes), respiratory conditions that impair oxygen uptake by the lungs, cardiovascular disorders that reduce oxygen delivery to tissues, anemia (reduced oxygen-carrying capacity of the blood), or conditions that impair oxygen utilization by cells.

Get a Free sample for the Hypoxia Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/hypoxia-market

Hypoxia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hypoxia Epidemiology Segmentation:

The Hypoxia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Hypoxia
• Prevalent Cases of Hypoxia by severity
• Gender-specific Prevalence of Hypoxia
• Diagnosed Cases of Episodic and Chronic Hypoxia

Download the report to understand which factors are driving Hypoxia epidemiology trends @ Hypoxia Epidemiology Forecast

Hypoxia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypoxia market or expected to get launched during the study period. The analysis covers Hypoxia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hypoxia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hypoxia Therapies and Key Companies

• RKER-012: Keros Therapeutics, Inc.
• Trans Sodium Crocetinate: Diffusion Pharmaceuticals
• Rejuveinix: Reven Pharmaceuticals
• RLS-0071: ReAlta Life Sciences, Inc
• Sargramostim: Partner Therapeutics, Inc
• Tirapazamine: Teclison Ltd.
• Belzutifan: Merck Sharp & Dohme
• Tirzepatide: Eli Lilly and Company
• TMS-007: Biogen
• Aes-103: AesRx, LLC
• TH-302: Threshold Pharmaceuticals
• GSK2256294: GlaxoSmithKline
• RO7070179: Roche
• GBT440: Global Blood Therapeutics
• AKB-6548: Akebia Therapeutics

Discover more about therapies set to grab major Hypoxia market share @ Hypoxia Treatment Landscape

Hypoxia Pipeline Market Drivers

• Increase in prevalence of Hypoxia, increase in the demand for disease specific novel treatment are some of the important factors that are fueling the Hypoxia Market. 

Scope of the Hypoxia Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hypoxia Companies: Keros Therapeutics, Inc., Diffusion Pharmaceuticals, Reven Pharmaceuticals, ReAlta Life Sciences, Inc, Partner Therapeutics, Inc, Teclison Ltd., Merck Sharp & Dohme, Eli Lilly and Company, Biogen, AesRx, LLC, Threshold Pharmaceuticals, GlaxoSmithKline, Roche, Global Blood Therapeutics, Akebia Therapeutics, and others
• Key Hypoxia Therapies: RKER-012, Trans Sodium Crocetinate, Rejuveinix, RLS-0071, Sargramostim, Tirapazamine, Belzutifan, Tirzepatide, TMS-007, Aes-103, TH-302, GSK2256294, RO7070179, GBT440, AKB-6548, and others
• Hypoxia Therapeutic Assessment: Hypoxia current marketed and Hypoxia emerging therapies
• Hypoxia Market Dynamics: Hypoxia market drivers and Hypoxia market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Hypoxia Unmet Needs, KOL’s views, Analyst’s views, Hypoxia Market Access and Reimbursement 

To know more about Hypoxia companies working in the treatment market, visit @ Hypoxia Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Hypoxia Market Report Introduction

2. Executive Summary for Hypoxia

3. SWOT analysis of Hypoxia

4. Hypoxia Patient Share (%) Overview at a Glance

5. Hypoxia Market Overview at a Glance

6. Hypoxia Disease Background and Overview

7. Hypoxia Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypoxia 

9. Hypoxia Current Treatment and Medical Practices

10. Hypoxia Unmet Needs

11. Hypoxia Emerging Therapies

12. Hypoxia Market Outlook

13. Country-Wise Hypoxia Market Analysis (2019–2032)

14. Hypoxia Market Access and Reimbursement of Therapies

15. Hypoxia Market Drivers

16. Hypoxia Market Barriers

17.  Hypoxia Appendix

18. Hypoxia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypoxia Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | ReAlta Life Sciences, Inc, Partner Therapeutics, Inc, Teclison Ltd., Merck Sharp & Dohme